1.Taylor DO, Edwards LB, Boucek MM, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult heart transplant report – 2007. J Heart Lung Transplant 2007; 26: 769–781.
2.Velez M, Johnson MR. Management of allosensitized cardiac transplant candidates. Transplant Rev (Orlando) 2009; 23: 235–247.
3.Itescu S, Schuster M, Burke E, et al. Immunologic consequences of assist devices. Cardiol Clin 2003; 21: 119–133.
4.Eckman PM. Immunosuppression in the sentisized heart transplant recipient. Curr Opin Organ Transplant 2010; 15: 650–656.
5.Jacobs JP, Quintessenza JA, Boucek RJ, et al. Pediatric cardiac transplantation in children with high panel reactive antibody. Ann Thorac Surg 2004; 78: 1703–1709.
6.Kobashigawa JA, Sabad A, Drinkwater D, et al. Pretransplant panel reactive-antibody screens. Are they truly a marker for poor outcome after cardiac transplantation? Circulation 1996; 94 (9 Suppl): II294–II297.
7.Nwakanma LU, Williams JA, Weiss ES, Russell SD, Baumgarter WA, Conte JV. Influence of pre-transplant panel-reactive antibody on outcomes in 8,160 heart transplant recipients in recent era. Ann Thorac Surg 2007; 84: 1556–1562; discussion 62-63.
8.Ballew CC, Bergin JD. Management of patients with preformed reactive antibodies who are awaiting cardiac transplantation. Am J Crit Care 2005; 14: 46–51.
9.Schuster M, Kocher A, John R, et al. B-cell activation and allosensitization after left ventricular assist device implantation is due to T-cell activation and CD40 ligand expression. Hum Immunol 2002; 63: 211–220.
10.Drakos SG, Stringham JC, Long JW, et al. Prevalence and risks of allosensitization in HeartMate left ventricular assist device recipients: the impact of leukofiltered cellular blood product transfusions. J Thorac Cardiovasc Surg 2007; 133: 1612–1619.
11.Joyce DL, Southard RE, Torre-Amione G, Noon GP, Land GA, Loebe M. Impact of left ventricular assist device-mediated humoral sensitization on post-transplant outcomes. J Heart Lung Transplant 2005; 24: 2054–2059.
12.Baran DA, Gass AL, Galin ID, et al. Lack of sensitization and equivalent post-transplant outcomes with the Novacor left ventricular assist device. J Heart Lung Transplant 2005; 24: 1886–1890.
13.Nikaein A, Cherikh W, Nelson K, et al. Organ procurement and transplantation network/united network of organ sharing histocompatibility committee collaborative study to evaluate prediction of crossmatch results in highly sensitized patients. Transplantation 2009; 87: 557–562.
14.Rhee JK, McGee E, Subacius H, et al. The impact of virtual crossmatch on cardiac allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant 2010; 29: S153.
15.Pisani BA, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701–706.
16.Leech SH, Lopez-Cepero M, LeFor WM, et al. Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin. Clin Transplant 2006; 20: 476–484.
17.John R, Lietz K, Burke E, et al. Intravenous immunoglobulin reduces anti-Human Leukocyte Antigen alloreactivity and shortens waiting time to cardiac transplantation in highly sensitized left ventricular assist device recipients. Circulation 1999; 100: II229–II235.
18.Itescu S, Burke E, Lietz K, et al. Intravenous pulse administration of Cyclophosphamide is an effective and safe treatment for sensitized cardiac allograft recipients. Circulation 2002; 105: 1214–1219.
19.Balfour IC, Fiore A, Graff RJ, Knutsen AP. Use of Rituximab to decrease panel-reactive antibodies. J Heart Lung Transplant 2005; 24: 628–630.
20.Becker YT, Samaniego-Picota M, Sollinger HW. The emerging role of Rituximab in organ transplantation. Transpl Int 2006; 19: 621–628.
21.Sidner RA, Book BK, Agarwal A, Bearden CM, Vieira CA, Pescovitz MD. In vivo human B-cell subset recovery after in vivo depletion with Rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies 2004; 13: 55–62.
22.Teuteberg JJ, Shullo MA, Zomak R, et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity immunosuppression: one year outcomes. Am J Transplant 2010; 10: 382–388.
23.Lick SD, Vaidya S, Kollar AC, et al. Peri-operative alemtuzumab (campath-1H) and plasmapheresis for high Panel Reactive Antibody positive lymphocyte crossmatch heart transplant: a strategy to shorten LVAD support. J Heart Lung Transplant 2008; 27: 1036–1039.
24.Trivedi HL, Terasaki PI, Feroz A, et al. Abrogation of anti-HLA antibodies via proteasome inhibition. Transplantation 2009; 87: 1555–1561.
25.Patel J, Kittelson M, Reed E, et al. The effectiveness of a standardized desensitization protocol in reducing calculated panel reactive antibodies in sensitized heart transplant candidates: does it make sense to desensitize? J Heart Lung Transplant 2010; 29: S103.
26.Holt DB, Lublin DM, Phelan DL, et al. Mortality and morbidity in pre-sensitized pediatric heart transplant recipients with a positive donor crossmatch utilizing peri-operative plasmapheresis and cytolytic therapy. J Heart Lung Transplant 2007; 26: 876–882.
27.Wright EJ, Fiser WP, Edens RE, et al. Cardiac transplant outcomes in pediatric patients with pre-formed anti-HLA antibodies and/or positive retrospective crossmatch. J Heart Lung Transplant 2007; 26: 1163–1169.
28.Pollock-BarZiv SM, den Hollander N, Ngan BY, et al. Pediatric heart transplantation in HLA sensitized patients: evolving management and assessment of intermediate-term outcomes in a high-risk population. Circulation 2007; 116 (1 Suppl): I-172–I-178.
29.Rossano JW, Morales DLS, Zafar F, et al. Impact of human leukocyte antigens on long-term outcome in pediatric heart transplant patients: an analysis of the United Network of Organ Sharing Database. J Thorac Cardiovasc Surg 2010; 140: 694–699.
30.Reed EF, Demetris AJ, Hammond E, et al. Acute antibody mediated rejection of cardiac transplants. J Heart Lung Transplant 2006; 25: 153–159.
31.Michaels PJ, Espejo ML, Kobashigawa J, et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003; 22: 58–69.
32.Smith RN, Brousaides N, Grazette L, et al. C4d deposition in cardiac allografts correlates with alloantibody. J Heart Lung Transplant 2005; 24: 1202–1210.
33.Rodriguez ER, Skojec DV, Tan CD, et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005; 5: 2778–2785.
34.Di Filippo S, Gimita A, Webber SA, et al. Impact of ELISA-detected anti-HLA antibodies on pediatric cardiac allograft outcome. Hum Immunol 2005; 66: 513–518.
35.Jacobs JP, Asante-Korang A, O'Brien SM, et al. Lessons learned from 119 consecutive cardiac transplants for pediatric and congenital heart disease. Ann Thorac Surg 2011; 91: 1248–1255; PMID:21440154, April, 2011.
36.Garrett HE Jr, Duvall-Seaman D, Helsley B, Groshart K. Treatment of vascular rejection with Rituximab in cardiac transplantation. J Heart Lung Transplant 2005; 24: 1337–1342.
37.Girnita AL, Webber SA, Zeevi A. Anti-HLA antibodies in pediatric solid organ transplantation. Pediatr Transplant 2006; 10: 146–153.
38.Taylor DO, Yowell RL, Kfoury AG, Hammond EH, Renlund DG. Allograft coronary artery disease: clinical correlations with circulating anti-HLA antibodies and the immunohistopathologic pattern of vascular rejection. J Heart Lung Transplant 2000; 19: 518–521.
39.Soleimani B, Lechler RI, Hornick PI, George AJ. Role of alloantibodies in the pathogenesis of graft arteriosclerosis in cardiac transplantation. Am J Transplant 2006; 6: 1781–1785.
40.Mancini D, Pinney S, Burkhoff D, et al. Use of rapamycin slows progression of cardiac transplantation vasculopathy. Circulation 2003; 108: 48–53.
41.Keogh A, Richardson M, Ruygrok P, et al. Sirolimus in de novo heart transplant recipients reduces acute rejection and prevents coronary artery disease at 2 years: a randomized clinical trial. Circulation 2004; 110: 2694–2700.
42.Eisen HJ, Tuzcu EM, Dorent R, et al. Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients. N Engl J Med 2003; 349: 847–858.
43.Costanzo MR, Dipchand A, Starling R, et al. The ISHLT Guidelines for the care of heart transplant recipients. J Heart Lung Transplant 2010; 29: 914–956.
44.Kobashigawa J, Mehra M, West L, et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009; 28: 213–225.
45.Tambur AR, Pamboukian SV, Costanzo MR, et al. The presence of HLA-directed antibodies after heart transplantation is associated with poor allograft outcome. Transplantation 2005; 80: 1019–1025.
46.Xydas S, Yang JK, Burke EM, et al. Utility of post-transplant anti-HLA antibody measurements in pediatric cardiac transplant recipients. J Heart Lung Transplant 2005; 24: 1289–1296.